Finance Watch: Amylyx, CinCor And Vigil Ready The First Biopharma IPOs Of 2022

Initial public offerings for US biopharmaceutical companies generally slowed as 2021 drew to a close and biotechnology stock valuations continued to fall below broader stock indices. Nevertheless, three firms – Amylyx Pharmaceuticals, Inc., CinCor Pharma, Inc. and Vigil Neuroscience, Inc.  – are gearing up to launch the first IPOs of 2022.

Last year closed with 107 biopharma first-time offerings in the US, which was a new record. However, the last five IPOs of 2021 followed the pattern of offerings that launched earlier in the year, with four out of five quickly trading below their IPO values. Amylyx, with a drug candidate under US Food and Drug Administration review for amyotrophic lateral sclerosis (ALS), has the potential to launch an offering that will outperform recent trends, given the late stage of its lead asset